Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells

ABSTRACT: Immunopeptidomic profiling of HLA-DR diverse monocyte-derived dendritic cells pulsed with SARS-CoV-2 spike (S) protein.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Dendritic Cell

SUBMITTER: Robert Parker

LAB HEAD: Nicola Ternette

PROVIDER: PXD021672 | Pride | 2021-07-09

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	HFX0070_COVID19_B721_C2_SPIKE_EVEN.mgf	Mgf
	HFX0070_COVID19_B721_C2_SPIKE_EVEN.raw	Raw
	HFX0070_COVID19_B721_C2_SPIKE_ODD.mgf	Mgf
	HFX0070_COVID19_B721_C2_SPIKE_ODD.raw	Raw
	HFX0070_COVID19_B721_C459_SPIKE_EVEN.mgf	Mgf

Items per page:

1 - 5 of 85

Publications

Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells.

Parker Robert R Partridge Thomas T Wormald Catherine C Kawahara Rebeca R Stalls Victoria V Aggelakopoulou Maria M Parker Jimmy J Powell Doherty Rebecca R Ariosa Morejon Yoanna Y Lee Esther E Saunders Kevin K Haynes Barton F BF Acharya Priyamvada P Thaysen-Andersen Morten M Borrow Persephone P Ternette Nicola N

Cell reports 20210513 8

Understanding and eliciting protective immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an urgent priority. To facilitate these objectives, we profile the repertoire of human leukocyte antigen class II (HLA-II)-bound peptides presented by HLA-DR diverse monocyte-derived dendritic cells pulsed with SARS-CoV-2 spike (S) protein. We identify 209 unique HLA-II-bound peptide sequences, many forming nested sets, which map to sites throughout S including glycosylated ...[more]

PMID: 34004174

Publication: 1/2

Similar Datasets

LC-MSMS of the MHC-I immunopeptidome of human iPSCs

Project description:The development of cancer immunotherapeutics is limited by the discovery of actionable tumor-specific antigens (TSAs), which need to be presented at high levels on cancer cells, but not presented by normal tissues or presented at levels below the threshold for T-cell recognition to prevent autoimmunity. Accumulating evidence indicates that pluripotent stem cells (PSCs), namely embryonic stem cells (ESCs) and induced PSCs (iPSCs), express a class of pluripotency-associated MHC-I-associated peptides (paMAPs) that can be recognized by tumor-specific T cells. Hence, being strictly confined to the embryonic stage of development and absent from healthy adult tissues, paMAPs shared by iPSCs and tumors would represent ideal targets for the development of TSA-based vaccines against a wide range of cancers. We performed immunopeptidomic analyses of human iPSCs and we identified a set of paMAPs that could serve for the design of TSA-based vaccines against many cancers.

2022-08-22 | PXD026702 | Pride

QuantitativeCancerProteomicAtlas1.2 observable peptides

Project description:This dataset contain evidences of observability of QCPA (v1.2) peptides, in whole cell tryptic proteome background.

2022-10-12 | PXD034653 | Pride

Influenza-derived peptide presentation by HLA-A*11:01

Project description:Analysis of the immunopeptidome of Human Leukocyte Antigen (HLA)-A*11:01 during influenza infection. Analyses were performed using the Class I reduced C1R cell line transfected with the HLA class I allele HLA-A*11:01.

2022-02-15 | PXD028985 | Pride

miR-132 mediates renal fibrosis

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2016-02-16 | E-GEOD-76550 | biostudies-arrayexpress

miR-132 mediates renal fibrosis: Genome-wide analysis of gene expression in foxd1-derivative interstital cells derived from fibrotic kidneys from mice treated with antagomir-132 or scramblemir

Project description:Chronic kidney disease is associated with progressive renal fibrosis, where perivascular cells give rise to the majority of Î±-SMA positive myofibroblasts. We sought to identify pericytic miRNAs that could serve as a target to decrease myofibroblast formation. We induced kidney fibrosis in FoxD1-GC;Z/Red-mice by unilateral ureteral obstruction (UUO) followed by FACS sorting of dsRed-positive FoxD1-derivative cells and miRNA profiling. MiR-132 selectively increased 21-fold during pericyte-to-myofibroblast formation whereas miR-132 was only 2.5-fold up in total kidney lysates (both in UUO and ischemia-reperfusion injury). MiR-132 silencing in UUO decreased collagen deposition (35%) and tubular apoptosis. Immunohistochemistry, western blot and qRT-PCR confirmed a similar decrease in interstitial Î±-SMA+ cells. Pathway analysis identified a rate-limiting role for miR-132 in myofibroblast proliferation that was confirmed in vitro. Indeed, antagomir-132 treated mice displayed a reduction in the number of proliferating, ki67+ interstitial myofibroblasts. Interestingly, this was selective for the interstitial compartment and did not impair the reparative proliferation of tubular epithelial cells, as evidenced by an increase in ki67+ epithelial cells, as well as increased (p-)RB1, Cyclin-A and decreased RASA1, p21 levels in kidney lysates. Taken together, silencing miR-132 counteracts the progression of renal fibrosis by selectively decreasing myofibroblast proliferation and could potentially serve as a novel antifibrotic therapy. Total RNA obtained from FACS sorted mouse renal FoxD1-derivatve interstitial cells from mice that were treated with antagomir-132 or scramblemir and underwent UUO (n=4)

2016-02-16 | E-GEOD-76548 | biostudies-arrayexpress

Presentation of DNAJB1-PRKACA fusion neoantigens by different HLA class I alleles

Project description:Fibrolamellar carcinoma (FLC) is a liver tumor with a high mortality burden and few treatment options. A promising therapeutic vulnerability in this disease is its highly conserved driver mutation: a gene fusion between DNAJB1 and PRKACA, which is expressed in virtually all FLC tumors and could be an ideal neoantigen target for immunotherapy. In this study, we aimed to define endogenous CD8 T cell responses to this fusion in FLC patients and evaluate fusion-specific T cell receptors (TCRs) as candidates for novel cellular immunotherapies. Although fusion-specific T cells in FLC appear to be rare, we nevertheless defined an endogenous functional T cell response in an FLC patient.

2024-05-24 | PXD042316 | Pride

Isolation of mouse and human MHC class I- and II-associated peptides for the analysis of immunopeptidomes by mass spectrometry

Project description:Immunopeptidomics is an emerging field that fuels and guides the development of vaccines and immunotherapies. More specifically, it refers to the science of investigating the composition of peptides presented by major histocompatibility complex (MHC) class I and class II molecules using mass spectrometry (MS) technology platforms. Among all the steps in a MS-based immunopeptidomic workflow, sample preparationis critically important for capturing high-quality data of therapeutic relevance. Here, we describe step-by-step instructions to isolate MHC class I and II-associated peptides by immunoaffinity purification from quality control (QC) samples. Our QC samples are MHC class I and class II peptides isolated from mouse (EL4 and A20) and human (JY) cell lines. We thoroughly describe the various reagents and specfic antibodies that are used too isolate MHC-associated peptides from these cell lines, including the steps to verify the beads-binding efficiency of the antibody and the elution efficiency of the MHC-peptide complexes from the beads. QC samples generated using the described protocol can be used to establish and standardize immunopeptidomic workflow, as well as to benchmark new protocols. We anticipate that the visualized protocol provided in this report will represent a great starting point for any non-expert in addition to foster the instra- and inter-laboratory reproducibility of the sample preparation procedure in immunopeptidomics.

2021-12-07 | PXD028633 | Pride

HLA-B*15:02 peptide presentation in the presence of carbamazepine and related molecules

Project description:Characterisation of peptides presented by the Human Leukocyte Antigen (HLA) class I molecule HLA-B*15:02 in the presence and absence of carbamazepine (CBZ), and related molecules carbamazepine-10,11-epoxide (ECBZ) and oxcarbazepine (OXC).

2021-03-23 | PXD023545 | Pride

HLA class II ligandome of C1R BLCL cell line

Project description:HLA-DR, -DQ and -DP ligands from transfected C1R cells were isolated using LB3.1, SPVL3 and B721 antibodies respectively.

2021-08-18 | PXD025877 | Pride

Influenza B-derived peptide presentation by HLA-B*07:02, -B*08:01 and -B*35:01

Project description:Analysis of peptide presentation by Human Leukocyte Antigen (HLA) class I of influenza B infected C1R cells expressing HLA-B*07:02, -B*08:01 or -B*35:01.

2024-03-04 | PXD045000 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data